Semax: The Complete Guide — Mechanism, Evidence, Dosing, and the NA-Semax-A Variant

Semax occupies a peculiar corner of the nootropic landscape: it has decades of clinical use in Russia, a well-characterized molecular mechanism, and a genuine evidence base — yet it remains almost completely unknown in Western medicine. If you've spent any time in cognitive enhancement communities, you've likely encountered it alongside its sister peptide Selank. This guide covers what Semax actually is, what the science shows, how it differs from Selank, the NA-Semax-A variant, and what responsible use looks like in 2025.

What Is Semax?

Semax is a synthetic heptapeptide based on a fragment of adrenocorticotropic hormone (ACTH). Specifically, it is an analogue of ACTH(4–7) — the four amino acid stretch of ACTH that carries neurotrophic activity — extended with a C-terminal Pro-Gly-Pro (PGP) sequence that protects the peptide from rapid enzymatic degradation in the nasal mucosa.

The full sequence is: Met-Glu-His-Phe-Pro-Gly-Pro.

This matters because full-length ACTH stimulates cortisol release from the adrenal glands — a property that would make it unsuitable as a daily cognitive enhancer. The ACTH(4–7) fragment retains the neurotrophic and cognitive-modulating properties of the parent hormone while completely losing its hormonal (adrenal-stimulating) activity. You get the brain effects without the cortisol spike.

Semax was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences through the 1980s and 1990s, with clinical development proceeding through the 1990s and early 2000s. It was registered by the Russian Ministry of Health for clinical use in 2011 for the treatment of cerebrovascular disorders, cognitive impairment, and optic nerve disease. It remains a prescription drug in Russia today.

The Mechanism: How Semax Works

Semax operates through several interlocking pathways, with BDNF upregulation being the most studied and most relevant for cognitive enhancement.

1. BDNF and NGF Upregulation

Brain-derived neurotrophic factor (BDNF) is often called "Miracle-Gro for the brain." It promotes the survival, growth, and differentiation of neurons; supports synaptic plasticity; and plays a central role in memory consolidation and learning. BDNF is critically important for long-term potentiation (LTP) — the cellular mechanism by which memories form and strengthen.

Semax increases BDNF mRNA expression in the hippocampus and prefrontal cortex within hours of administration. A 2007 study by Davydova et al. demonstrated BDNF elevation in rat hippocampal tissue after Semax administration, with sustained upregulation lasting beyond the peptide's direct pharmacological window. This suggests Semax doesn't just acutely mimic BDNF — it triggers the gene expression machinery to produce more of it.

Nerve growth factor (NGF) is similarly upregulated, particularly relevant for cholinergic neurons in the basal forebrain — neurons that are among the first to degenerate in Alzheimer's disease. This NGF-upregulating property is part of why Semax has been investigated in age-related cognitive decline contexts.

2. Dopaminergic and Serotonergic Modulation

Semax modulates both the dopaminergic and serotonergic systems, which explains its focus-enhancing and mood-elevating properties. Animal studies show increased dopamine turnover in the striatum and prefrontal cortex after Semax administration. Unlike conventional stimulants (which directly release or block reuptake of dopamine), Semax appears to modulate these systems more indirectly — a softer, more sustainable effect profile without the rebound and tolerance that characterize amphetamine-class compounds.

The serotonergic effects are smaller but present, contributing to the mild mood elevation and anxiolytic qualities at lower doses. At higher doses (500+ mcg), the dopaminergic stimulation tends to dominate — which is why some users report restlessness or mild anxiety at the high end of the dosing range.

3. Neuroprotection via Anti-Inflammatory Signaling

One of Semax's most clinically significant effects is neuroprotection in ischemic conditions. After ischemic stroke, a cascade of inflammatory and excitotoxic events kills neurons in the penumbra — the tissue surrounding the core infarct that is damaged but potentially salvageable. Semax has been shown to reduce the expression of pro-inflammatory cytokines (including TNF-α and IL-1β) in brain tissue and to protect neurons from excitotoxic death in rodent ischemia models.

This mechanistic work underpins Semax's approved clinical use in Russia for stroke rehabilitation — not as a cure, but as a neuroprotective and recovery-enhancing adjunct during the critical post-stroke window.

4. Enhancement of Neural Plasticity

Beyond BDNF elevation, Semax has been shown to increase dendritic branching and synaptic density in hippocampal tissue in preclinical models. This structural change — not just functional modulation — suggests that Semax's cognitive effects may involve genuine neuroplastic remodeling, particularly with repeated use over weeks. This is consistent with user reports of a "ramp-up" effect, where benefits become more apparent after 5–7 days of consistent use rather than on day one.

The Russian Clinical History

Semax has a clinical history that is unusual by Western standards: long, proprietary, and largely unpublished in English-language journals. Understanding this history is important for calibrating how much weight to give the evidence.

Development began under Soviet-era military and academic research programs in the 1980s. The goal was to develop cognitive-enhancing compounds that could improve performance in high-stress, cognitively demanding environments — think astronauts, military pilots, and nuclear facility operators. ACTH fragments were already known to have memory-enhancing effects in animals; the challenge was engineering stability and selectivity.

By the early 1990s, Semax had entered clinical investigation in Russia for:

• Ischemic stroke recovery — post-stroke cognitive impairment and neurological deficit reduction
• Optic nerve disease — including glaucoma and ischemic optic neuropathy
• Attention and learning disorders in children
• General cognitive impairment in the elderly

In 2011, Semax was officially registered by the Russian Ministry of Health for clinical use. It is manufactured by the State Research Institute of Highly Pure Biopreparations in Saint Petersburg and distributed as a 0.1% or 1% intranasal solution under the brand name Semax.

The clinical trials supporting registration were conducted in Russia, primarily at Russian academic medical centers, with sample sizes ranging from 50 to approximately 200 participants. The published findings show consistent positive effects on cognitive outcomes, neurological recovery post-stroke, and optic nerve function — but the studies have not been independently replicated in Western academic settings, and some have methodological limitations common to older Soviet-era clinical research (open-label designs, limited placebo controls in some trials).

Cognitive Enhancement: What the Evidence Shows

The most studied cognitive effects of Semax are in populations with existing impairment — post-stroke patients, elderly patients with vascular cognitive decline, and patients with optic nerve disease. The extrapolation to healthy, high-functioning individuals is less directly supported but mechanistically plausible given the BDNF and dopamine mechanisms.

Memory and Learning

Russian clinical trials in elderly patients with mild-to-moderate cognitive impairment consistently show improvements in short-term memory, working memory span, and information processing speed after 5–14 day Semax courses. The improvements are modest to moderate in absolute terms and tend to persist for 2–4 weeks after the treatment course ends — consistent with the neurotrophic (not just acute pharmacological) mechanism.

In healthy young adults, the evidence is primarily anecdotal and self-reported. The nootropic community's consensus — such as it is — is that Semax is most noticeable for:

• Verbal fluency — finding words faster, more articulate speech
• Working memory — holding and manipulating more information simultaneously
• Focus and sustained attention — reduced distractibility during demanding cognitive work
• Mental clarity — reduction of "brain fog," particularly in the AM window

These effects are typically rated as subtle-to-moderate — more "the sharpest version of yourself on a good day" than dramatic cognitive transformation. Semax is not Limitless.

Stroke Recovery

This is the strongest application of Semax and the one with the most robust (within the constraints of Russian clinical research) evidence base. Multiple trials demonstrate that Semax administered in the acute and subacute phases after ischemic stroke improves neurological outcomes, reduces infarct volume in animal models, and accelerates functional recovery.

The neuroprotective mechanism is particularly relevant here: Semax reduces the secondary inflammatory cascade that kills neurons in the penumbra following the initial ischemic event. By limiting excitotoxic and inflammatory damage, it preserves tissue that would otherwise be lost during the critical 24–72 hour post-stroke window.

Some Russian neurology departments use Semax as part of standard post-stroke rehabilitation protocols — not as a replacement for thrombolysis or mechanical thrombectomy, but as an adjunct during the recovery phase. This clinical use, backed by registration, distinguishes Semax from purely experimental compounds.

Anxiety and Depression (Adjunct Use)

Semax has documented anxiolytic effects at lower doses, though these are more modest than those of its sister peptide Selank. The anxiolytic profile is mediated primarily through serotonergic modulation and BDNF upregulation (BDNF is increasingly recognized as a core mediator of antidepressant response). Some Russian studies report mood improvement and reduced anxiety in cognitively impaired elderly patients, though whether this reflects direct mood effects or secondary improvement from cognitive gains is unclear.

In practical terms: Semax is more cognitively stimulating and less anxiolytic than Selank. Users who need anxiety reduction alongside cognitive enhancement often stack the two, using Selank in the evening and Semax in the morning — a common protocol in the Russian biohacker community.

Semax vs. Selank: Key Differences

The standard characterization: if Selank is the anxiolytic that improves cognition as a secondary benefit, Semax is the cognitive enhancer that has some mild anxiolytic properties. They are genuine complements — which is why the alternating protocol (Semax AM, rest, Selank cycle) is so popular.

N-Acetyl Semax Amidate (NA-Semax-A): The Enhanced Variant

NA-Semax-A (also written NA-Semax Amidate or simply "NA-Semax") is a chemically modified version of Semax that adds two stability-enhancing modifications:

1. N-terminal acetylation (N-Acetyl): Protects the N-terminus from aminopeptidase degradation in the nasal mucosa, extending the active half-life
2. C-terminal amidation (Amidate): Protects the C-terminus from carboxypeptidase degradation, further extending stability

Together, these modifications make NA-Semax-A significantly more resistant to enzymatic degradation in the nasal mucosa and bloodstream. The practical implications:

• Lower effective dose: Most users report comparable effects at roughly half the dose of standard Semax — 100–300 mcg vs. 200–600 mcg
• Longer duration of action: Extended stability means the peptide remains active for longer after nasal administration
• Higher cost: The chemical synthesis is more complex, and NA-Semax-A typically costs 50–100% more per milligram than standard Semax

Is NA-Semax-A strictly "better"? Not necessarily — it depends on use case. At equivalent biological activity, the effects are similar. For those titrating carefully or on a budget, standard Semax at the right dose is indistinguishable in practice. NA-Semax-A becomes more relevant when bioavailability is a concern (dry nasal passages, imprecise dosing technique) or when users want to minimize total volume administered.

Dosing Protocols

Standard Semax Dosing

Semax is administered intranasally — nasal drops or a nasal spray device. Subcutaneous injection is technically possible but rarely used in practice, as intranasal delivery achieves adequate CNS exposure via olfactory transport and is far more convenient.

The Russian clinical dosing (from registered medical use) is typically 200–900 mcg/day, divided across 1–3 doses. For cognitive enhancement protocols in healthy individuals, most experienced users operate in the lower portion of this range:

Key timing rules:

• Dose in the morning or early afternoon only. Semax has stimulating properties and will disrupt sleep if taken late in the day.
• Start at the low end (200 mcg) and titrate up over several days. Individual response varies considerably.
• Don't dose every day indefinitely. Cycling — 10–14 days on, equal time off — is the standard approach in both clinical practice and the nootropic community. The neurotrophic effects of a course persist beyond the dosing window, making breaks both safe and practically sensible.

NA-Semax-A Dosing

Apply a 50–60% dose reduction relative to standard Semax as a starting point:

• Entry: 100–150 mcg once daily (AM)
• Experienced: 150–300 mcg once daily or split AM/early afternoon

Reconstitution (if using lyophilized powder)

Research-grade Semax often comes as a lyophilized powder requiring reconstitution with bacteriostatic water or sterile saline. Standard reconstitution for a 5mg vial:

• Add 2.5 mL bacteriostatic water → 2,000 mcg/mL (2 mcg/µL)
• At 200 mcg per dose: draw 0.1 mL (10 units on a 100-unit insulin syringe)
• Apply to nasal mucosa via nasal dropper or repurposed spray pump

Use the Reconstitution Calculator to verify your specific vial size and target dose.

Safety Profile and Side Effects

Semax's safety profile, as reported in Russian clinical literature and by the research community, is favorable for a compound with this level of CNS activity. That said, the absence of large, independent, long-term safety studies in the Western literature means the safety profile should be considered incompletely characterized.

Commonly Reported Effects

• Mild stimulation at moderate-to-high doses: Increased alertness, reduced appetite, occasionally mild restlessness. This is dose-dependent and typically manageable by staying at 300 mcg or below.
• Nasal irritation: Mild irritation or discomfort in the nasal passage, particularly with higher concentrations or prolonged daily use. A 0.1% solution is gentler than 1%.
• Headache: Occasionally reported, particularly at higher doses or during the first 1–2 days of a new course.
• Vivid dreams or sleep disruption: Primarily a problem with late-day dosing. Strict AM-only timing eliminates this for most users.

What Has Not Been Reported

• No dependence or addiction: No withdrawal syndrome, no craving, no escalating dose requirement documented in Russian clinical use.
• No tolerance in standard cycling: The cycling protocol (on/off) appears to preserve responsiveness. Some users report reduced effects with continuous daily use over 3+ weeks — consistent with neurotrophic system downregulation.
• No hormonal effects: Semax does not stimulate cortisol, does not affect the HPA axis, and does not require post-cycle therapy of any kind.

Contraindications and Cautions

• Anxiety disorders: Higher doses can exacerbate anxiety in predisposed individuals. Start at the low end; consider Selank instead or alongside.
• Psychosis risk: The dopaminergic stimulation is a theoretical concern in individuals with schizophrenia spectrum disorders or first-degree relatives with such disorders. Avoid.
• Pregnancy and breastfeeding: No safety data. Avoid.
• Active cancers: BDNF and NGF have growth-promoting properties. While no evidence links Semax to cancer promotion, the theoretical concern exists with sustained neurotrophic stimulation. Consult oncology.

Stacking Semax with Selank

The Semax + Selank stack is well-documented in the Russian nootropic community and makes intuitive mechanistic sense. The two peptides have complementary — not redundant — profiles:

• Semax: BDNF upregulation, dopaminergic stimulation, focus, memory consolidation, mild stimulant
• Selank: GABAergic anxiolytic, serotonin modulation, stress resilience, anti-anxiety — without sedation

Together, they address the "anxious stimulant" problem that many users encounter with Semax alone: the focus benefits are preserved while the restlessness and irritability are dampened by Selank's anxiolytic action.

Common approaches:

1. Same-session stack: Semax AM dose first, Selank 30–60 minutes later or simultaneously. 200–400 mcg of each. This is the "drive + calm" approach.
2. Time-segregated: Semax in the morning, Selank in the evening. Each compound handles a different part of the day.
3. Alternating cycles: 14 days Selank, 10-day rest, 14 days Semax. Sequential rather than concurrent — useful for those who want to isolate the effects of each. See the full cycling protocol on the Protocols page.

There are no known interactions or safety concerns with the Semax + Selank combination. Both are administered intranasally and neither has documented interactions with the other's mechanism.

Semax and Other Peptides: Stacking Considerations

Semax is generally compatible with other peptides given its non-hormonal, non-immunosuppressive mechanism. A few relevant combinations:

• Semax + BPC-157: Complementary — one central, one peripheral. No interaction concerns. BPC-157's systemic anti-inflammatory and gut-protective effects don't overlap with Semax's CNS neurotrophic mechanism.
• Semax + GHK-Cu: Both upregulate neurotrophins (GHK-Cu induces NGF); theoretically additive for neuroprotection. No adverse interaction data.
• Semax + GLP-1 agonists (semaglutide): GLP-1 receptors are expressed in the brain and GLP-1 agonists have independently documented neuroprotective effects. No known interaction with Semax; mechanistically non-overlapping.
• Semax + stimulants (caffeine, modafinil): Use caution. Semax is mildly stimulating; stacking with other stimulants can push toward restlessness, anxiety, and disrupted sleep at doses that would be individually manageable. Reduce Semax dose if combining.

How to Source Semax

In Russia, Semax is a prescription medication available at pharmacies as a 0.1% or 1% nasal solution. For users outside Russia:

Research peptide vendors sell lyophilized Semax and NA-Semax-A powder. Quality varies significantly. When evaluating vendors, look for:

• Third-party HPLC and mass spectrometry testing (not just COAs from internal testing)
• Sequence verification — the peptide sequence should be confirmed by MS, not assumed
• Certificate of Analysis (COA) with purity ≥98% for HPLC
• Established vendor reputation in research communities — check forums for recent quality reports

Be aware: research peptide vendors sell Semax for research purposes only and cannot legally market it for human use in the US or EU. The legal status is a gray area — possession for personal use is generally not prosecuted, but the sale for human use is restricted.

Frequently Asked Questions

The Bottom Line

Semax sits in an unusual position among research peptides: it has a well-characterized mechanism, decades of clinical use in Russia, genuine (if limited-by-Western-standards) evidence for cognitive enhancement and neuroprotection, and a favorable safety profile with minimal risk of dependence. For a compound operating outside of Western regulatory frameworks, that's a relatively strong foundation.

What it isn't: a dramatic cognitive enhancer in the stimulant sense, a replacement for fundamentals (sleep, exercise, stress management), or a compound with the kind of large, independent, multi-site RCT evidence that should inform clinical decisions. Use the evidence it has — not the evidence you wish it had.

If you're considering Semax, start at 200 mcg intranasally in the morning, cycle it in 10–14 day blocks, and pay attention to how your sleep, appetite, and anxiety levels respond. Stack with Selank if anxiety is a concern. Log your results in the WellSourced Journal to track patterns over time.

For dosing calculations, vial reconstitution math, and protocol planning, the WellSourced Tools page has Semax built into the dosage reference and reconstitution calculator.